Optimizing Intralesional Triamcinolone Dosing for Hidradenitis Suppurativa

• Status: Not yet recruiting
• Trial end date: 2022-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Currently, there is limited evidence showing increased resolution of HS flares with higher doses of intralesional triamcinolone (ILTAC) as well as a difference in side effect profile between the doses. The goal of this study is to determine the efficacy of treating HS flares with ILTAC-10, ILTAC-20 and ILTAC-40 and to investigate the side effect profile for each dose.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Montefiore Medical Center
• Treatments: Triamcinolone; Triamcinolone Acetonide; Triamcinolone diacetate; Triamcinolone hexacetonide

Criteria

Inclusion Criteria:

• Age > 13 years old.

• Subject must voluntarily sign and date an informed consent, approved by an independent ethics committee / institutional review board.

• Subject is willing to comply with the procedures in this protocol.

• The subject must be diagnosed with HS and receiving care at HSC

• Subjects with Hidradenitis Suppurativa Physician Global Assessment (HS-PGA) score between 2 and 5

• The subject must have an inflamed nodule or abscess at the time of enrollment.

Exclusion Criteria:

• The subject has an HS-PGA score of 0 or 1

• The subject has received ILTAC less than 8 days prior to the initial visit.

• The subject does not have capacity to consent to the study.

• The subject is has taken systemic steroids at least 4 weeks prior to the time of enrollment.

• The subject has a known allergy or history of adverse reaction to steroids.

• The subject is pregnant.

• Subjects who have received a biologic therapy two weeks before and during the study period.